Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Brentuximab”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02744612
What this trial is testing

Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Who this might be right for
Recurrent Hodgkin LymphomaRefractory Hodgkin Lymphoma
City of Hope Medical Center 39
Early research (Phase 1)Ended earlyNCT01940796
What this trial is testing

Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD)

Who this might be right for
Graft-vs-Host DiseaseGVHD
Massachusetts General Hospital 19
Large-scale testing (Phase 3)Looking for participantsNCT04685616
What this trial is testing

Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

Who this might be right for
Hodgkin Lymphoma
University College, London 1,042
Testing effectiveness (Phase 2)UnknownNCT05006664
What this trial is testing

Brentuximab Vedotin in Combination With CHEP in Patient With PTCL

Who this might be right for
Lymphoma, T-Cell, Peripheral
Czech Lymphoma Study Group 33
Testing effectiveness (Phase 2)Study completedNCT02927769
What this trial is testing

Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment

Who this might be right for
Hodgkin Disease
Bristol-Myers Squibb 72
Testing effectiveness (Phase 2)Ended earlyNCT01805037
What this trial is testing

Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas

Who this might be right for
Adult Grade III Lymphomatoid GranulomatosisAdult Nasal Type Extranodal NK/T-cell LymphomaAnaplastic Large Cell Lymphoma+114 more
Northwestern University 20
Early research (Phase 1)WithdrawnNCT03373305
What this trial is testing

Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas

Who this might be right for
CD30-Positive Neoplastic Cells PresentFolliculotropic Mycosis FungoidesRecurrent Mycosis Fungoides+4 more
City of Hope Medical Center
Testing effectiveness (Phase 2)Study completedNCT02298283
What this trial is testing

Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD

Who this might be right for
Hodgkin Lymphoma
The Lymphoma Academic Research Organisation 40
Large-scale testing (Phase 3)Enrolling By InvitationNCT07258680
What this trial is testing

BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell Lymphomas

Who this might be right for
Peripheral T-cell Lymphoma
N.N. Petrov National Medical Research Center of Oncology 114
Testing effectiveness (Phase 2)Study completedNCT01476410
What this trial is testing

Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma

Who this might be right for
Adult Lymphocyte Depletion Hodgkin LymphomaAdult Lymphocyte Predominant Hodgkin LymphomaAdult Mixed Cellularity Hodgkin Lymphoma+4 more
Northwestern University 49
Large-scale testing (Phase 3)Study completedNCT01100502
What this trial is testing

Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)

Who this might be right for
Disease, Hodgkin
Seagen Inc. 329
Testing effectiveness (Phase 2)Active Not RecruitingNCT03007030
What this trial is testing

Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery

Who this might be right for
CD30-Positive Neoplastic Cells PresentMalignant Mesothelioma
M.D. Anderson Cancer Center 25
Large-scale testing (Phase 3)Looking for participantsNCT05595447
What this trial is testing

Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma

Who this might be right for
Hodgkin LymphomaRefractory Hodgkin LymphomaRelapsed Hodgkin's Disease, Adult
Hospital Regional de Alta Especialidad del Bajio 20
Early research (Phase 1)WithdrawnNCT03205891
What this trial is testing

Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas

Who this might be right for
Malignant Neoplasms Stated as Primary Lymphoid HaematopoieticClassical Hodgkin LymphomaAnaplastic Large Cell Lymphoma+1 more
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)WithdrawnNCT02623920
What this trial is testing

Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
Diffuse Large B Cell LymphomaMediastinal Large B-cell LymphomaGrey Zone Lymphoma+4 more
University of Arizona
Testing effectiveness (Phase 2)Study completedNCT00947856
What this trial is testing

A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study

Who this might be right for
Disease, HodgkinLymphoma, Large-Cell, AnaplasticLymphoma, Non-Hodgkin
Seagen Inc. 110
Testing effectiveness (Phase 2)Looking for participantsNCT05180097
What this trial is testing

Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

Who this might be right for
Hodgkin Lymphoma
Canadian Cancer Trials Group 84
Testing effectiveness (Phase 2)Study completedNCT01851200
What this trial is testing

Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors

Who this might be right for
Germ Cell Cancer
Fondazione Michelangelo 9
Testing effectiveness (Phase 2)Study completedNCT01807598
What this trial is testing

Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia

Who this might be right for
Aggressive Systemic MastocytosisMast Cell LeukemiaSystemic Mastocytosis
Jason Robert Gotlib 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT01920932
What this trial is testing

Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma

Who this might be right for
Stage II Childhood Hodgkin LymphomaStage III Childhood Hodgkin LymphomaStage IV Childhood Hodgkin Lymphoma
St. Jude Children's Research Hospital 77
Next Page